tradingkey.logo
tradingkey.logo
Search

Bone Biologics Corp

BBLG
Add to Watchlist
1.420USD
+0.020+1.43%
Close 07/02, 13:00ETQuotes delayed by 15 min
2.55MMarket Cap
LossP/E TTM

More Details of Bone Biologics Corp Company

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Bone Biologics Corp Info

Ticker SymbolBBLG
Company nameBone Biologics Corp
IPO dateNov 27, 2015
CEOFrelick (Jeffrey)
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 27
Address2 Burlington Woods Dr Ste 100
CityBURLINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01803-4551
Phone17815524452
Websitehttps://www.bonebiologics.com/
Ticker SymbolBBLG
IPO dateNov 27, 2015
CEOFrelick (Jeffrey)

Company Executives of Bone Biologics Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of Bone Biologics Corp?

The top five shareholders of Bone Biologics Corp are: Mr. Jeffrey Frelick

How many institutions hold shares of Bone Biologics Corp (BBLG)?

As of 2026Q1, 17 institutions hold shares of Bone Biologics Corp, with a combined market value of approximately 58.41K, accounting for 3.25% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 22009.00.